173 related articles for article (PubMed ID: 35315502)
21. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3).
Kandala PK; Srivastava SK
BMC Med; 2012 Jan; 10():9. PubMed ID: 22280969
[TBL] [Abstract][Full Text] [Related]
22. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis.
Singh S; Sadanandam A; Nannuru KC; Varney ML; Mayer-Ezell R; Bond R; Singh RK
Clin Cancer Res; 2009 Apr; 15(7):2380-6. PubMed ID: 19293256
[TBL] [Abstract][Full Text] [Related]
23. Interleukin‑8 released by cancer‑associated fibroblasts attenuates the autophagy and promotes the migration of ovarian cancer cells.
Thongchot S; Jamjuntra P; Therasakvichya S; Warnnissorn M; Ferraresi A; Thuwajit P; Isidoro C; Thuwajit C
Int J Oncol; 2021 May; 58(5):. PubMed ID: 33649784
[TBL] [Abstract][Full Text] [Related]
24. Noncanonical IL6 Signaling-Mediated Activation of YAP Regulates Cell Migration and Invasion in Ovarian Clear Cell Cancer.
Azar WJ; Christie EL; Mitchell C; Liu DS; Au-Yeung G; Bowtell DDL
Cancer Res; 2020 Nov; 80(22):4960-4971. PubMed ID: 32917727
[TBL] [Abstract][Full Text] [Related]
25. IL‑6 prevents CXCL8‑induced stimulation of EpCAM expression in ovarian cancer cells.
Kapka-Skrzypczak L; Popek S; Sawicki K; Drop B; Czajka M; Jodłowska-Jędrych B; Matysiak-Kucharek M; Furman-Toczek D; Zagórska-Dziok M; Kruszewski M
Mol Med Rep; 2019 Mar; 19(3):2317-2322. PubMed ID: 30747214
[TBL] [Abstract][Full Text] [Related]
26. Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells.
Chen X; Tian J; Su GH; Lin J
Curr Cancer Drug Targets; 2019; 19(5):417-427. PubMed ID: 29714141
[TBL] [Abstract][Full Text] [Related]
27. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling.
Wang Y; Ma H; Zhao C; Liu T; Yan D; Jou D; Li H; Zhang C; Lü J; Li C; Lin J; Li S; Lin L
Oncotarget; 2017 May; 8(20):33683-33693. PubMed ID: 28430601
[TBL] [Abstract][Full Text] [Related]
28. Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.
Liu C; Lou W; Armstrong C; Zhu Y; Evans CP; Gao AC
Prostate; 2015 Sep; 75(13):1341-53. PubMed ID: 25970160
[TBL] [Abstract][Full Text] [Related]
29. [Effects of siltuximab on the interleukin-6/Stat3 signaling pathway in ovarian cancer].
Guo YQ; Lu P; Duan ZF; Zhang Z
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):854-9. PubMed ID: 21211286
[TBL] [Abstract][Full Text] [Related]
30. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.
Liu L; Zhang Z; Zhang G; Wang T; Ma Y; Guo W
J Transl Med; 2020 Sep; 18(1):357. PubMed ID: 32951601
[TBL] [Abstract][Full Text] [Related]
31. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.
Wen W; Liang W; Wu J; Kowolik CM; Buettner R; Scuto A; Hsieh MY; Hong H; Brown CE; Forman SJ; Horne D; Morgan R; Wakabayashi M; Dellinger TH; Han ES; Yim JH; Jove R
Mol Cancer Ther; 2014 Dec; 13(12):3037-48. PubMed ID: 25319391
[TBL] [Abstract][Full Text] [Related]
32. Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance.
Li E; Hu Z; Sun Y; Zhou Q; Yang B; Zhang Z; Cao W
Tumour Biol; 2016 Jun; 37(6):7843-52. PubMed ID: 26695152
[TBL] [Abstract][Full Text] [Related]
33. Treatment with β-elemene combined with paclitaxel inhibits growth, migration, and invasion and induces apoptosis of ovarian cancer cells by activation of STAT-NF-κB pathway.
Xiaomeng F; Lei L; Jinghong A; Juan J; Qi Y; Dandan Y
Braz J Med Biol Res; 2020; 53(6):e8885. PubMed ID: 32401925
[TBL] [Abstract][Full Text] [Related]
34. Targeting estrogen receptor subtypes (ERα and ERβ) with selective ER modulators in ovarian cancer.
Chan KK; Leung TH; Chan DW; Wei N; Lau GT; Liu SS; Siu MK; Ngan HY
J Endocrinol; 2014 May; 221(2):325-36. PubMed ID: 24819599
[TBL] [Abstract][Full Text] [Related]
35. Prucalopride Inhibits Proliferation of Ovarian Cancer Cells via Phosphatidylinositol 3-Kinase (PI3K) Signaling Pathway.
Liu X; Xu Y; Zhang L; Liu T; Zhang H
Med Sci Monit; 2018 Jun; 24():4137-4145. PubMed ID: 29909423
[TBL] [Abstract][Full Text] [Related]
36. High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097.
He W; Luistro L; Carvajal D; Smith M; Nevins T; Yin X; Cai J; Higgins B; Kolinsky K; Rizzo C; Packman K; Heimbrook D; Boylan JF
Mol Oncol; 2011 Jun; 5(3):292-301. PubMed ID: 21315665
[TBL] [Abstract][Full Text] [Related]
37. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.
Sankpal UT; Ingersoll SB; Ahmad S; Holloway RW; Bhat VB; Simecka JW; Daniel L; Kariali E; Vishwanatha JK; Basha R
Tumour Biol; 2016 Oct; 37(10):14259-14269. PubMed ID: 27581819
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-6 and interleukin-8 serum levels in prognosis of hormone-dependent breast cancer.
Milovanović J; Todorović-Raković N; Radulovic M
Cytokine; 2019 Jun; 118():93-98. PubMed ID: 29482885
[TBL] [Abstract][Full Text] [Related]
39. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma.
Ma H; Yan D; Wang Y; Shi W; Liu T; Zhao C; Huo S; Duan J; Tao J; Zhai M; Luo P; Guo J; Tian L; Mageta L; Jou D; Zhang C; Li C; Lin J; Lv J; Li S; Lin L
Cancer Sci; 2019 Mar; 110(3):950-961. PubMed ID: 30648776
[TBL] [Abstract][Full Text] [Related]
40. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
